Kampanjeplan Autolus Therapeutics plc
Om selskapet
Autolus Therapeutics plc, биофармацевтическая компания, работающая на клинической стадии, разрабатывает Т-клеточную терапию для лечения рака. Компания разрабатывает AUTO1 и AUTO3 для лечения В-клеточных злокачественных новообразований; AUTO2 и AUTO8 для лечения множественной миеломы; AUTO1 / 22 для лечения CAR-T с двойным нацеливанием; AUTO3NG для лечения гематологического рака; AUTO4 и AUTO5 для Т-клеточной лимфомы; AUTO6NG для лечения запрограммированной терапии Т-клетками; AUTO6 для лечения нейробластомы; и AUTO7 для лечения рака простаты.
Flere detaljerP/S | 177.71 |
---|---|
P/BV | 2.03 |
EV/EBITDA | -2.49 |
EBITDA | -0.1332 |
Цена ао | 4.26 |
Сайт | http://www.autolus.com |
Число акций ао | 0.17394 млрд |
Выручка | 0.0029 |
Див.доход ао | 0 |
ISIN | US05280R1005 |
Валюта | usd |
IPO date | 2018-06-22 |
Sector | Health Care |
Industry | Biotechnology |
Валюта отчета | usd |
Prisendring per dag: | +0.7299% (4.11) |
---|---|
Prisendring per uke: | +4.02% (3.98) |
Prisendring per måned: | +4.81% (3.95) |
Prisendring over 3 måneder: | -7.9% (4.495) |
Prisendring over seks måneder: | -14.81% (4.86) |
Prisendring per år: | +81.98% (2.275) |
Prisendring over 3 år: | -38.67% (6.75) |
Prisendring over 5 år: | -62.8% (11.13) |
Prisendring siden begynnelsen av året: | -6.97% (4.45) |
|
Undervurdering
|
Effektivitet
|
|||||||||||||||||||||||||||||||||||||
Utbytte
|
Plikt
|
Vekstimpuls
|
Institusjoner | Volum | Dele, % |
---|---|---|
Syncona Portfolio Ltd | 21346829 | 8.03 |
Blackstone Inc | 20485611 | 7.7 |
Paradigm Biocapital Advisors LP | 12611335 | 4.74 |
Deep Track Capital, LP | 11869297 | 4.46 |
TFG Asset Management GP Ltd | 8000000 | 3.01 |
Cormorant Asset Management, LP | 5450000 | 2.05 |
Armistice Capital, LLC | 3850000 | 1.45 |
Adage Capital Partners GP L.L.C. | 3825532 | 1.44 |
Frazier Life Sciences Management, L.P. | 3746857 | 1.41 |
Price (T.Rowe) Associates Inc | 3001208 | 1.13 |
ETF | Dele, % | Lønnsomhet for året, % | Utbytte, % |
---|---|---|---|
Virtus LifeSci Biotech Clinical Trials ETF | 0.65217 | 63.040315712071 | 0.33 |
ProShares Ultra Nasdaq Biotechnology | 0.0513 | 51.697637072723 | 0.85651 |
Range Cancer Therapeutics ETF | 0.92787 | 47.24446537918 | 0.11955 |
SPDR S&P International Small Cap ETF | 0.04123 | 8.9378151260504 | 3.10348 |
Invesco Nasdaq Biotechnology ETF | 0.07395 | 28.578975171685 | 0.8565 |
SPDR S&P Kensho New Economies Composite ETF | 0.103 | 28.602833414753 | 0.88486 |
Principal Healthcare Innovators ETF | 0.07215 | 618.4964157054 | 0.8416 |
Future Tech ETF | 0.07215 | 426.33969118983 | 0.8416 |
Veileder | Stillingstittel | Betaling | Fødselsår |
---|---|---|---|
Mr. Christopher Vann | Senior VP & COO | N/A | 1965 (59 år) |
Mr. David Brochu | Senior VP & Chief Technical Officer | N/A | 1956 (68 år) |
Mr. Brent Rice | Senior VP, Chief Commercial Officer & Site Head of US | N/A | 1966 (58 år) |
Dr. Christian Martin Itin Ph.D. | CEO & Director | 2.43M | 1964 (60 år) |
Dr. Martin Pule M.D., MBBS | Founder, Senior VP & Chief Scientific Officer | N/A | 1972 (52 år) |
Mr. Robert F. Dolski | Senior VP & CFO | 1971 (53 år) | |
Mr. Alexander Swan | Senior VP & Chief Human Resources Officer | 1965 (59 år) | |
Ms. Olivia Manser | Director of Investor Relations | ||
Mr. Alex Driggs | Senior VP of Legal Affairs & General Counsel and Secretary | ||
Dr. Chris Williams | Senior VP & Chief Business Development Officer | 1980 (44 år) |
Nettsted: http://www.autolus.com